REFERENCES
2. Kremeike K, Wetter RML, Burst V, Voltz1 R, Kuhr K, et al. Prevalence of hyponatremia in inpatients with incurable and life-limiting diseases and its association with physical symptoms-a retrospective descriptive study. Support Care Cancer 2018;26:213-22.
3. Wald R, Jaber BL, Price LL. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170:294-302.
4. Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Pinha IL, et al. OPTIME-CHF investigators lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation 2005;111:2454-60.
5. Rusinaru D, Tribouilloy C, Berry C, Richards AM, Whalley GA, et al. MAGGIC investigators: relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): meta-analysis global group in chronic heart failure (MAGGIC). Eur J Heart Fail 2012;14:1139-46.
6. Price JF, Kantor PF, Shaddy RE, Rossano JW, Goldberg JF, et al. Incidence, severity, and association with adverse outcome of hyponatremia in children hospitalized with heart failure. Am J Cardiol 2016;118:1006-10.
7. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857-65.
8. Choi JS, Kim CS, Bae EH, Ma SK, Ahn YK, et al. Prognostic impact of hyponatremia occurring at various time points during hospitalization on mortality in patients with acute myocardial infarction. Medicine (Baltimore) 2017;96:e7023.
9. Zilberberg MD, Exuzides A, Spalding J, Foreman A, Jones AG, et al. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulm Med 2008;8:16.
10. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26.
11. Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) 2017;5:104-12.
12. Sun L, Hou Y, Xiao Q, Du Y. Association of serum sodium and risk of all-cause mortality in patients with chronic kidney disease: a meta-analysis and sysematic review. Sci Rep 2017;7:15949.
13. Zhou XY, Chen HL, Ni SS. Hyponatremia and short-term prognosis of patients with acute pulmonary embolism: a meta-analysis. Int J Cardiol 2017;227:251-6.
14. Carcel C, Sato S, Zheng D, Heeley E, Arima H, et al. Prognostic significance of hyponatremia in acute intracerebral hemorrhage: pooled analysis of the intensive blood pressure reduction in acute cerebral hemorrhage trial studies. Crit Care Med 2016;44:1388-94.
15. Terzian C, Frye EB, Piotrowski ZH. Admission hyponatremia in the elderly: factors influencing prognosis. J Gen Intern Med 1994;9:89-91.
16. Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, et al. The epidemiology of intensive care unit-acquired hyponatremia and hypernatraemia in medical-surgical intensive care units. Crit Care 2008;12:R162.
17. Martin JY, Goff BA, Urban RR. Preoperative hyponatremia in women with ovarian cancer: an additional cause for concern? Gynecol Oncol 2016;142:471-6.
18. Kagase A, Yamamoto M, Shimura T, Kodama A, Kano S, et al. Impact of pre-procedural hyponatremia on clinical outcomes after transcatheter aortic valve replacement: a propensity-matched analysis. Catheter Cardiovasc Interv 2018;92:E125-34.
19. Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One 2013;8:e80451.
20. Elsayem A, Mori M, Parsons HA, Munsell MF, Hui D, et al. Predictors of inpatient mortality in an acute palliative care unit at a comprehensive cancer center. Support Care Cancer 2010;18:67-76.
21. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012;59:222-8.
22. Berardi R, Caramanti M, Castagnani M, Guglielmi S, Marcucci F, et al. Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patient. Support Care Cancer 2015;23:3095-101.
23. Castillo JJ, Glezerman IG, Boklage SH, Chiodo J 3rd, Tidwell BA, et al. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer 2016;16:564.
24. Goldvaser H, Rozen-Zvi B, Yerushalmi R, Gafter-Gvili A, Lahav M, et al. Malignancy associated SIADH: characterization and clinical implications. Acta Oncol 2016;55:1190-5.
25. Yoon J, Ahn SH, Lee YJ, Kim CM. Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support Care Cancer 2015;23:1735-40.
26. Liao H, Zhu Z, Rong X, Wang H, Peng Y. Hyponatremia is a potential predictor of progression in radiation-induced brain necrosis: a retrospective study. BMC Neurol 2018;18:130.
27. Hsu HH, Chen YC, Tian YC, Chan YL, Kuo MC, et al. Role of serum sodium in assessing hospital mortality in cancer patients with spontaneous tumour lysis syndrome inducing acute uric acid nephropathy. Int J Clin Pract 2009;63:751-6.
28. Selmer C, Madsen JC, Torp-Pedersen C, Gislason GH, Faber J. Hyponatremia, all-cause mortality, and risk of cancer diagnoses in the primary care setting: a large population study. Eur J Intern Med 2016;36:36-43.
29. Vasudev NS, Brown JE, Brown SR, Rafiq R, Morgan R, et al. Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res 2008;14:1775-81.
30. Jeppesen AN, Jensen HK, Donskov F, Marcussen N, von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010;102:867-72.
31. Furukawa J, Miyake H, Kusuda Y, Fujisawa M. Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor. Int J Clin Oncol 2015;20:351-7.
32. Kim HS, Yi SY, Jun HJ, Lee J, Park JO, et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 2007;73:192-7.
33. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the barcelona clinic liver cancer system. Hepatology 2013;57:112-9.
34. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 2000;8:192-7.
35. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia. Clin J Am Soc Nephrol 2011;6:960-5.
36. Shepshelovich D, Leibovitch C, Klein A, Zoldan S, Milo G, Shochat T, et al. The syndrome of inappropriate antidiuretic hormone secretion: distribution and characterization according to etiologies. Eur J Intern Med 2015;26:819-24.
37. Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, et al. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget 2017;8:23871-9.
38. Penttilä P, Bono P, Peltola K, Donskov F. Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. Acta Oncol 2018;57:1580-5.
39. Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, et al. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One 2015;10:e0124105.
40. Havard M, Dautry F, Tchénio T. A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells. J Biol Chem 2011;286:44177-86.
41. Benvenuti S, Deledda C, Luciani P, Modi G, Bossio A, et al. Low extracellular sodium causes neuronal distress independently of reduced osmolality in an experimental model of chronic hyponatremia. Neuromolecular Med 2013;15:493-503.
43. Yadav B, Greish K. Selective inhibition of hemeoxygenase-1 as a novel therapeutic target for anticancer treatment. J Nanomedic Nanotechnol 2011;S4:5.
44. Bhandari S, Peri A, Cranston I, McCool R, Shaw A, Glanville J, et al. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clin Endocrinol (Oxf) 2017;86:761-71.
45. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
